These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 22313548

  • 1. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction.
    Schwenkglenks M, Toward TJ, Plent S, Szucs TD, Blackman DJ, Baumbach A.
    Heart; 2012 Apr; 98(7):544-51. PubMed ID: 22313548
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes.
    Schwenkglenks M, Brazier JE, Szucs TD, Fox KA.
    Value Health; 2011 Jan; 14(1):24-33. PubMed ID: 21211483
    [Abstract] [Full Text] [Related]

  • 3. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
    Cohen DJ, Lincoff AM, Lavelle TA, Chen HL, Bakhai A, Berezin RH, Jackman D, Sarembock IJ, Topol EJ.
    J Am Coll Cardiol; 2004 Nov 02; 44(9):1792-800. PubMed ID: 15519009
    [Abstract] [Full Text] [Related]

  • 4. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.
    Pinto DS, Stone GW, Shi C, Dunn ES, Reynolds MR, York M, Walczak J, Berezin RH, Mehran R, McLaurin BT, Cox DA, Ohman EM, Lincoff AM, Cohen DJ, ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Investigators.
    J Am Coll Cardiol; 2008 Nov 25; 52(22):1758-68. PubMed ID: 19022155
    [Abstract] [Full Text] [Related]

  • 5. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
    Olchanski N, Slawsky KA, Plent S, Kado C, Cyr PL.
    Hosp Pract (1995); 2010 Nov 25; 38(4):138-46. PubMed ID: 21068538
    [Abstract] [Full Text] [Related]

  • 6. Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results.
    Mishkel GJ, Moore AL, Markwell SJ, Ligon RW.
    J Invasive Cardiol; 2007 Feb 25; 19(2):63-8. PubMed ID: 17268039
    [Abstract] [Full Text] [Related]

  • 7. Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model.
    Borg S, Persson U, Allikmets K, Ericsson K.
    Clin Ther; 2006 Nov 25; 28(11):1947-59. PubMed ID: 17213015
    [Abstract] [Full Text] [Related]

  • 8. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
    Rajagopal V, Lincoff AM, Cohen DJ, Gurm HS, Hu T, Desmet WJ, Kleiman NS, Bittl JA, Feit F, Topol EJ.
    Am Heart J; 2006 Jul 25; 152(1):149-54. PubMed ID: 16824845
    [Abstract] [Full Text] [Related]

  • 9. Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal.
    Simpson EL, Fitzgerald P, Evans P, Tappenden P, Kalita N, Reckless JP, Bakhai A.
    Pharmacoeconomics; 2013 Apr 25; 31(4):269-75. PubMed ID: 23512147
    [Abstract] [Full Text] [Related]

  • 10. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G, Neumann FJ, Deliargyris EN, Mehran R, Mehilli J, Ferenc M, Schulz S, Schömig A, Kastrati A, Stone GW.
    Circ Cardiovasc Interv; 2012 Oct 25; 5(5):705-12. PubMed ID: 23048052
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bivalirudin: a pharmacoeconomic profile of its use in patients with acute coronary syndromes.
    Lyseng-Williamson KA.
    Pharmacoeconomics; 2011 Apr 25; 29(4):343-59. PubMed ID: 21395353
    [Abstract] [Full Text] [Related]

  • 13. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
    Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW, HORIZONS-AMI Trial Investigators.
    Lancet; 2009 Oct 03; 374(9696):1149-59. PubMed ID: 19717185
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R, Sardar P, Amin H, Swaminathan RV, Kim LK, Chatterjee S, Feldman DN.
    Am J Cardiol; 2014 Jul 15; 114(2):250-9. PubMed ID: 24890986
    [Abstract] [Full Text] [Related]

  • 16. Cost analysis of bivalirudin versus reference anticoagulants without GP IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention for acute coronary syndrome in routine clinical practice. Pompidou registry.
    Puymirat E, Cohen S, Védrenne G, Caruba T, Sabatier B, Danchin N, Durand E.
    Ann Cardiol Angeiol (Paris); 2013 Apr 15; 62(2):89-94. PubMed ID: 23245394
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials.
    Dangas GD, Schoos MM, Steg PG, Mehran R, Clemmensen P, van 't Hof A, Prats J, Bernstein D, Deliargyris EN, Stone GW.
    Circ Cardiovasc Interv; 2016 May 15; 9(5):e003272. PubMed ID: 27165710
    [Abstract] [Full Text] [Related]

  • 19. One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial.
    Fabris E, Kilic S, Van't Hof AWJ, Ten Berg J, Ayesta A, Zeymer U, Hamon M, Soulat L, Bernstein D, Anthopoulos P, Deliargyris EN, Steg PG.
    JAMA Cardiol; 2017 Jul 01; 2(7):791-796. PubMed ID: 28273285
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.